ES2176721T3 - Nuevo uso de compuestos del amonio y/o urea. - Google Patents
Nuevo uso de compuestos del amonio y/o urea.Info
- Publication number
- ES2176721T3 ES2176721T3 ES97914690T ES97914690T ES2176721T3 ES 2176721 T3 ES2176721 T3 ES 2176721T3 ES 97914690 T ES97914690 T ES 97914690T ES 97914690 T ES97914690 T ES 97914690T ES 2176721 T3 ES2176721 T3 ES 2176721T3
- Authority
- ES
- Spain
- Prior art keywords
- infant
- urea
- sids
- pap
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S297/00—Chairs and seats
- Y10S297/08—Inflatable bellows
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Abstract
SE DESCRIBE EL USO DE UN COMPUESTO DE AMONIO FISIOLOGICAMENTE INOCUO Y/O DE UREA COMO ADITIVO PARA UN PREPARADO PARA LACTANTES O UNA PAPILLA, O PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA PARA LA PROFILAXIS DEL SINDROME DE MUERTE SUBITA DEL LACTANTE (MSL), ASI COMO UN PREPARADO PARA LACTANTES O UNA PAPILLA QUE CONTIENE, JUNTO CON INGREDIENTES CONVENCIONALES, UN COMPUESTO DE AMONIO FISIOLOGICAMENTE INOCUO Y/O UREA. ADEMAS, SE DESCRIBE UN METODO PARA PREVENIR LA MSL, CUYO METODO INCLUYE LA ADMINISTRACION AL LACTANTE DE UN PREPARADO PARA LACTANTES O UNA PAPILLA COMO LOS INDICADOS ANTERIORMENTE, Y UN METODO PARA LA PROFILAXIS DE LA MSL, EN EL QUE SE ADMINISTRA AL LACTANTE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COMPUESTO DE AMONIO FISIOLOGICAMENTE INOCUO Y/O UREA, O SE ADMINISTRA AL TRACTO GASTROINTESTINAL DEL LACTANTE UNA BACTERIA NO PATOGENA, APROPIADAMENTE SELECCIONADA O MODIFICADA, PRODUCTORA DE UREASA. FINALMENTE, SE DESCRIBE UN METODO PARA EL DIAGNOSTICO DEL RIESGO DE MSL SEGUN CUYO METODO SE ANALIZAN LAS HECES DEL LACTANTE CON RESPECTO A PRESENCIA DE UREA, ACTIVIDAD DE LA UREASA Y/O IONES AMONIO, INDICANDO LA PRESENCIA DE UREA, LA AUSENCIA O VALORES ANORMALMENTE BAJOS DE ACTIVIDAD DE LA UREASA Y LOS IONES AMONIO, RESPECTIVAMENTE, RIESGO DE MSL.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9601057A SE507696C2 (sv) | 1996-03-20 | 1996-03-20 | Användning av en fysiologisk ofarlig ammoniumförening och/ eller urea för profylax av plötslig spädbarnsdöd samt sätt att diagnostisera risk för plötslig spädbarnsdöd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2176721T3 true ES2176721T3 (es) | 2002-12-01 |
Family
ID=20401857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97914690T Expired - Lifetime ES2176721T3 (es) | 1996-03-20 | 1997-03-04 | Nuevo uso de compuestos del amonio y/o urea. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6333055B1 (es) |
| EP (1) | EP0888112B1 (es) |
| JP (1) | JP2000507936A (es) |
| AT (1) | ATE219935T1 (es) |
| AU (1) | AU722642B2 (es) |
| CA (1) | CA2249704A1 (es) |
| DE (1) | DE69713746T2 (es) |
| DK (1) | DK0888112T3 (es) |
| ES (1) | ES2176721T3 (es) |
| NO (1) | NO984194L (es) |
| NZ (1) | NZ331185A (es) |
| PT (1) | PT888112E (es) |
| SE (1) | SE507696C2 (es) |
| WO (1) | WO1997034590A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572528B1 (en) | 2012-08-06 | 2017-02-21 | Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center | Monitor for SIDS research and prevention |
| EP3646739A1 (en) | 2018-11-01 | 2020-05-06 | N.V. Nutricia | Nutritional composition comprising urea and non-digestible oligosaccharides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4668772A (en) * | 1984-11-27 | 1987-05-26 | Nestec S.A. | Methods for controlling the viscosity of protein hydrolysates |
| CA1297721C (en) * | 1987-01-26 | 1992-03-24 | Shalan A. Al-Mashiki | PROCESS FOR LOWERING THE CONCENTRATION OF .beta.-LACTOGLOBULIN IN CHEESE WHEY |
| US5312839A (en) | 1991-03-05 | 1994-05-17 | Regents Of The University Of California | Compounds and method for protection of cells and tissues from irreversible injury due to lactic acidosis |
| US5169666A (en) * | 1991-11-14 | 1992-12-08 | The United States Of America As Represented By The Secretary Of Agriculture | Preparation of simulated human milk protein by low temperature microfiltration |
| AUPM864894A0 (en) | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
-
1996
- 1996-03-20 SE SE9601057A patent/SE507696C2/sv not_active IP Right Cessation
-
1997
- 1997-03-04 JP JP9533393A patent/JP2000507936A/ja active Pending
- 1997-03-04 US US09/142,145 patent/US6333055B1/en not_active Expired - Fee Related
- 1997-03-04 ES ES97914690T patent/ES2176721T3/es not_active Expired - Lifetime
- 1997-03-04 NZ NZ331185A patent/NZ331185A/xx unknown
- 1997-03-04 PT PT97914690T patent/PT888112E/pt unknown
- 1997-03-04 AT AT97914690T patent/ATE219935T1/de not_active IP Right Cessation
- 1997-03-04 EP EP97914690A patent/EP0888112B1/en not_active Expired - Lifetime
- 1997-03-04 DE DE69713746T patent/DE69713746T2/de not_active Expired - Fee Related
- 1997-03-04 WO PCT/SE1997/000361 patent/WO1997034590A1/en active IP Right Grant
- 1997-03-04 CA CA002249704A patent/CA2249704A1/en not_active Abandoned
- 1997-03-04 AU AU21840/97A patent/AU722642B2/en not_active Ceased
- 1997-03-04 DK DK97914690T patent/DK0888112T3/da active
-
1998
- 1998-09-11 NO NO984194A patent/NO984194L/no not_active Application Discontinuation
-
2001
- 2001-11-15 US US09/987,558 patent/US20030021856A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6333055B1 (en) | 2001-12-25 |
| ATE219935T1 (de) | 2002-07-15 |
| DE69713746D1 (de) | 2002-08-08 |
| CA2249704A1 (en) | 1997-09-25 |
| PT888112E (pt) | 2002-11-29 |
| NZ331185A (en) | 2000-05-26 |
| NO984194D0 (no) | 1998-09-11 |
| EP0888112A1 (en) | 1999-01-07 |
| AU2184097A (en) | 1997-10-10 |
| JP2000507936A (ja) | 2000-06-27 |
| DE69713746T2 (de) | 2002-11-21 |
| DK0888112T3 (da) | 2002-10-21 |
| SE9601057D0 (sv) | 1996-03-20 |
| SE9601057L (sv) | 1997-09-21 |
| EP0888112B1 (en) | 2002-07-03 |
| US20030021856A1 (en) | 2003-01-30 |
| SE507696C2 (sv) | 1998-07-06 |
| WO1997034590A1 (en) | 1997-09-25 |
| NO984194L (no) | 1998-09-11 |
| AU722642B2 (en) | 2000-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200901979T2 (tr) | Antikolinerjik etkili bileşik ve ?-mimetikler bazında yeni ilaç bileşimleri. | |
| BR0314236A (pt) | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos | |
| NO20014415D0 (no) | Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens | |
| MXPA02011632A (es) | Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1. | |
| EP0145779A4 (en) | PREPARATION AND PROCESS FOR THE TREATMENT OF ACNE. | |
| WO1992019617A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| IE41374B1 (en) | A composition for treating schizophrenia | |
| DE60022895D1 (de) | Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| DE69030616D1 (de) | Pharmazeutische Zusammensetzungen zur Hemmung der Maillardreaktion | |
| YOW et al. | Toxicity of Polymyxin B: II. Human Studies with Particular Reference to Evaluation of Renal Function | |
| Schou et al. | Human pharmacokinetics and safety of boric acid | |
| ES2106531T3 (es) | Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso. | |
| ES2176721T3 (es) | Nuevo uso de compuestos del amonio y/o urea. | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| FR2794976B1 (fr) | Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane | |
| ATE219689T1 (de) | Diagnostische zusammensetzung | |
| Harding et al. | The pharmacokinetic behaviour of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates | |
| Weidner et al. | Chronic bacterial prostatitis: therapeutic experience with ciprofloxacin | |
| Aguiar et al. | Development of oxytetracycline long-acting injectable | |
| Hayton et al. | Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients | |
| Grunberg et al. | Triamterene-induced nephrolithiasis | |
| Boyd et al. | Isoniazid | |
| Fishbein | 11. Hydroxamic Acids as Urease Inhibitors for Medical and Veterinary Use | |
| File Jr et al. | Evaluation of cefoperazone in the therapy of urinary tract infections | |
| SOHN et al. | Sulfadimethoxine Use in Chronic Urinary Drainage |